Related Experiment Videos
Sensitive, specific radioimmunoassay for quantifying pergolide in plasma.
R R Bowsher1, J M Apathy, J A Compton
1Department of Drug Disposition & Bioanalytical Research, Eli Lilly and Co., Wishard Memorial Hospital, Indianapolis, IN 46202.
Clinical Chemistry
|October 1, 1992
Summary
A new radioimmunoassay accurately measures pergolide in Parkinson disease patients. This method reliably quantifies low pergolide plasma concentrations, aiding treatment monitoring.
Area of Science:
- Pharmacology
- Analytical Chemistry
- Neuroscience
Background:
- Pergolide is a synthetic ergoline used for Parkinson disease treatment.
- Low plasma concentrations of pergolide present analytical challenges.
- Radioimmunoassay (RIA) is effective for analyzing related ergolines.
Purpose of the Study:
- To develop a sensitive and specific radioimmunoassay for pergolide.
- To establish a reliable method for quantifying pergolide in plasma.
Main Methods:
- Development of a radioimmunoassay for pergolide.
- Utilization of a monoclonal antibody to enhance specificity.
- Validation of the assay in toxicology and clinical studies.
Main Results:
- The radioimmunoassay has a detection limit of 21 ng/L and a working range of 100-1000 ng/L.
- High specificity was achieved, with low cross-reactivity to pergolide sulfoxide.
- The assay demonstrated acceptable performance over two years in animal and human studies.
Conclusions:
- The developed radioimmunoassay is a valid method for quantifying therapeutic pergolide concentrations in plasma.
- This assay facilitates better monitoring of pergolide therapy in Parkinson disease patients.